Skip to main content
. 2015 Jul 6;112(29):E3855–E3863. doi: 10.1073/pnas.1510733112

Fig. S2.

Fig. S2.

EGFR TKIs paradoxically activate ERK1/2 in EGFR-mutated NSCLC cells. (AD) Western blot analysis. Exponentially growing HCC827 cells were treated with erlotinib (A and B) or lapatinib (C and D) at the indicated concentrations and collected after 1 h (A and C) and 6 h (B and D) of treatment.